Hyperion Surgical Names Jonathan Stapley as Vice President of Commercial Operations
News originally published by
EIN PresswireStapley to leverage extensive medtech experience to build go-to-market strategy as company continues development of its IVY intelligent vascular access platform
Throughout my career, I’ve seen that the technologies that succeed are the ones that solve a real clinical pain point and deliver clear value to the health system.”
WESTON, FL, UNITED STATES, November 18, 2026 /EINPresswire.com/ -- Hyperion Surgical, an innovative medical technology company committed to transforming difficult IV access, has appointed Jonathan Stapley as Vice President of Commercial Operations. Stapley will lead the company’s commercialization strategy and go-to-market plans for Hyperion’s IVY™ intelligent vascular access platform, which is currently under development.— Jonathan Stapley, Vice President of Commercial Operations
“Jonathan has years of experience building and scaling commercial strategies for innovative medtech organizations and he has a proven track record of supporting the delivery of novel technologies from early adoption to standard of care,” said Dr. Eric Peterson, CEO and Founder of Hyperion Surgical. “Difficult IV access affects millions of patients every year, and hospitals are ready for a better answer. As we prepare to bring our novel IVY platform to market, Jonathan’s experience with health system leaders, clinicians, and value analysis committees will be essential to making reliable vascular access a reality at the bedside.”
Stapley has more than two decades of senior-level experience in the medical device industry, including commercial strategy, marketing, product management, and corporate development. He has a deep understanding of the healthcare marketplace and the commercial considerations involved in introducing innovative technologies, building customer relationships, and driving market adoption.
“Throughout my career, I’ve seen that the technologies that succeed are the ones that solve a real clinical pain point and deliver clear value to the health system,” said Stapley. “I’m excited about IVY because it is being designed to do both. I look forward to partnering with clinicians and hospital leaders to help make IVY the new standard of care for difficult vascular access.”
Prior to joining Hyperion, he served as Senior Director of Marketing for B. Braun Medical where he led all product management activities for the company’s active device portfolio. He has held leadership positions at Terumo Medical Corp, Teleflex, KCI (now Solventum), and Adhezion Biomedical (now H.B. Fuller). He also served on the board of directors of June Medical.
He holds an MBA from the University of Texas at Austin's McCombs School of Business and a bachelor's degree from Brigham Young University.
About Hyperion Surgical
Hyperion Surgical, Inc. is modernizing one of healthcare’s most persistent clinical challenges: the high variability and failure rate in difficult-to-access IV placements. Hyperion’s IVYTM intelligent vascular access platform combines real-time imaging, AI-assisted vessel targeting, and clinician-controlled robotic catheter placement into one integrated solution. Founded by an innovative team of clinical experts and world-class engineers, Hyperion’s mission is to transform difficult IV access from a time-consuming and frustrating process into a reliable and consistent outcome for patients and clinicians. To learn more, visit www.hyperionsurgical.com or follow us on LinkedIn.
The Hyperion IVY™ platform is under development and has not been reviewed or cleared by the U.S. Food and Drug Administration. It is not available for sale.
##
Travis Small
Hyperion Surgical
+1 617-538-9041
tsmall@sloweymcmanus.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
